Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News

Welcome to the Cambridge Angels

Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News
Arecor due to transfer formulation for new medicine to Hikma Pharmaceuticals in first half of 2022
27 December 2021
Cambridge Angels
Arecor due to transfer formulation for new medicine to Hikma Pharmaceuticals in first half of 2022
Cambridge Angels
27 December 2021

Arecor due to transfer formulation for new medicine to Hikma Pharmaceuticals in first half of 2022

Cambridge Angels
27 December 2021

Source:https://www.cambridgeindependent.co.uk/business/arecor-due-to-transfer-formulation-for-new-medicine-to-hikma-9232629/

Newer PostThis rare metal could soon be replaced in mobile phone screens
Older PostPrivitar Supports Broader Use and Sharing of Data Across Borders with Introduction of NOVLT Tokenization
LI-In-Bug_small.png
Back to Top
Privacy
info@cambridgeangels.net